Dr. Robert Davey, PhD is a currently a Professor of Microbiology at the Chobanian and Avedisian School of Medicine. Dr. Davey received his doctorate in Microbiology and Immunology at the University of Adelaide in Australia. He continued his training as a Postdoctoral Fellow at the Howard Hughes Medical Institute and then at the Division of Hematology, both with Dr. James Cunningham at Brigham and Women’s Hospital and Harvard Medical School.
Dr. Davey’s first academic appointment was as an Instructor in Medicine at Harvard. He then held an Assistant Professor position which he got promoted to Adjunct Associate Professor at the Department of Microbiology and Immunology at the University of Texas Medical Branch.
Dr. Davey was also a Ewing Halsell Scholar and Scientist at the Department of Virology and Immunology at the Texas Biomedical Research Institute. As a Scientist at the Texas Biomedical Research Institute, Dr. Davey’s work was focused on identification of cellular factors important for establishing infection by filovirus and bunyaviruses. His work has culminated in a deeper understanding of the entry and cell signaling pathways that are used by these viruses to penetrate the cell membrane and establish infection. His work with Ebolavirus has been published in the high-impact journals PLoS Pathogens, PNAS and a new article on host factor dependence in Science that was featured on the cover page. Dr. Davey’s group works collaboratively with a number of groups providing sophisticated molecular biology and cell biology techniques for the study of pathogenic viruses including Ebolavirus for which the lab mainly works. He has developed high throughput screening techniques for Ebolavirus. He also performs contract work testing drugs and compounds for ebolavirus infection inhibition. His team is well trained in ABSL4 procedures and have been working with Ebolavirus since 2006.
From 2015-2017, Dr. Davey held the role of Interim Chair in the Department of Virology and Immunology at the Texas Biomedical Research Institute. He is also Director of ABSL4 at the Texas Biomedical Research Institute.
- Faculty, National Emerging Infectious Disease Lab, Boston University
- Member, Evans Center for Interdisciplinary Biomedical Research, Boston University Chobanian & Avedisian School of Medicine
- Graduate Faculty (Primary Mentor of Grad Students), Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences
- Published on 6/24/2022
Mishra N, Teyra J, Boytz R, Miersch S, Merritt TN, Cardarelli L, Gorelik M, Mihalic F, Jemth P, Davey RA, Sidhu SS, Leung DW, Amarasinghe GK. Monoclonal antibodies binding data for SARS-CoV-2 proteins. Data Brief. 2022 Aug; 43:108415. PMID: 35789908.
- Published on 5/27/2022
Gourronc FA, Rebagliati MR, Kramer-Riesberg B, Fleck AM, Patten JJ, Geohegan-Barek K, Messingham KN, Davey RA, Maury W, Klingelhutz AJ. Adipocytes are susceptible to Ebola Virus infection. Virology. 2022 Aug; 573:12-22. PMID: 35690007.
- Published on 4/8/2022
Mishra N, Teyra J, Boytz R, Miersch S, Merritt TN, Cardarelli L, Gorelik M, Mihalic F, Jemth P, Davey RA, Sidhu SS, Leung DW, Amarasinghe GK. Development of Monoclonal Antibodies to Detect for SARS-CoV-2 Proteins. J Mol Biol. 2022 May 30; 434(10):167583. PMID: 35405107.
- Published on 3/31/2022
Plescia CB, Lindstrom AR, Quintero MV, Keiser P, Anantpadma M, Davey R, Stahelin RV, Davisson VJ. Evaluation of Phenol-Substituted Diphyllin Derivatives as Selective Antagonists for Ebola Virus Entry. ACS Infect Dis. 2022 May 13; 8(5):942-957. PMID: 35357134.
- Published on 9/21/2021
El-Sayed NS, Jureka AS, Edwards MR, Lohan S, Williams CG, Keiser PT, Davey RA, Totonchy J, Tiwari RK, Basler CF, Parang K. Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus. Eur J Med Chem. 2021 Dec 15; 226:113862. PMID: 34583312.
- Published on 8/25/2021
Lennemann NJ, Dillard J, Ruggio N, Cooney AL, Schaack GA, Davey RA, Maury W. A Naturally Occurring Polymorphism in the Base of Sudan Virus Glycoprotein Decreases Glycoprotein Stability in a Species-Dependent Manner. J Virol. 2021 08 25; 95(18):e0107321. PMID: 34232742.
- Published on 8/2/2021
Batra J, Mori H, Small GI, Anantpadma M, Shtanko O, Mishra N, Zhang M, Liu D, Williams CG, Biedenkopf N, Becker S, Gross ML, Leung DW, Davey RA, Amarasinghe GK, Krogan NJ, Basler CF. Non-canonical proline-tyrosine interactions with multiple host proteins regulate Ebola virus infection. EMBO J. 2021 09 15; 40(18):e105658. PMID: 34260076.
- Published on 5/11/2021
Morselli Gysi D, do Valle Í, Zitnik M, Ameli A, Gan X, Varol O, Ghiassian SD, Patten JJ, Davey RA, Loscalzo J, Barabási AL. Network medicine framework for identifying drug-repurposing opportunities for COVID-19. Proc Natl Acad Sci U S A. 2021 05 11; 118(19). PMID: 33906951.
- Published on 4/27/2021
Mena EL, Donahue CJ, Vaites LP, Li J, Rona G, O'Leary C, Lignitto L, Miwatani-Minter B, Paulo JA, Dhabaria A, Ueberheide B, Gygi SP, Pagano M, Harper JW, Davey RA, Elledge SJ. ORF10-Cullin-2-ZYG11B complex is not required for SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2021 04 27; 118(17). PMID: 33827988.
- Published on 4/22/2021
Patten JJ, Keiser PT, Gysi D, Menichetti G, Mori H, Donahue CJ, Gan X, Do Valle I, Geoghegan-Barek K, Anantpadma M, Berrigan JL, Jalloh S, Ayazika T, Wagner F, Zitnik M, Ayehunie S, Anderson D, Loscalzo J, Gummuluru S, Namchuk MN, Barabasi AL, Davey RA. Multidose evaluation of 6,710 drug repurposing library identifies potent SARS-CoV-2 infection inhibitors In Vitro and In Vivo. bioRxiv. 2021 Apr 22. PMID: 33907750.
View 97 more publications: View full profile at BUMC